ArticleBlood2025

Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.

Jaclyn Andricovich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.